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 Abstract 
  Background:   Apolipoprotein A1 (apoA1) is the major apolipoprotein constituent of the high-
density lipoprotein (HDL) and is involved in reverse cholesterol transport. Variation in the apoA1 
gene might influence the function of the protein and, thus, brain cholesterol metabolism, lead-
ing to an increased risk for Alzheimer’s disease (AD).  Aim:  In the current report, we investigated 
the role of the functional apoA1 polymorphism (–75 G/A) as a genetic risk factor for AD in a Tu-
nisian population.   Methods:   173 AD patients and 150 healthy controls were studied.   Results:  
No association was found between this genetic variation in apoA1 gene and the risk of AD. The 
presence of the (–75 G/A) A allele appeared, however, to be associated with lower levels of ce-
rebrospinal fluid A    42 and HDL cholesterol levels in sera.   Conclusion:   Our data support the 
observation that apoA1 polymorphism influences cholesterol metabolism and A  42 deposition 
in the brain. 
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 Introduction 
  Alzheimer’s disease (AD) is the most common form of dementia in elderly people   [1, 2]  . 
Estimates suggest that     10% of individuals over the age of 65 and almost half over the age 
of 85 have Alzheimer’s dementia. As human life expectancy continues to rise, the total num-
ber of affected individuals is also expected to increase dramatically   [3]  .
    AD is a multifactorial disease but its etiology and pathophysiology are still not fully un-
derstood  [4] . AD probably results from a complex interaction between aging  [5] , vascular risk 
factors   [6, 7]  , impaired status of micronutrients   [8]  , and genetic factors   [9]  . Three genes have 
been identified as causative genes in familial AD: the amyloid precursor protein (APP), pre-
senilin-1 and presenilin-2   [10]  . In addition, the apolipoprotein E (apoE)     4 allele is the only 
recognized genetic risk factor for familial as well as sporadic AD   [11, 12]  . Although many 
studies have reported associations between genes involved in cholesterol metabolism and 
AD, the functional connection between the cholesterol pathway and AD pathology has not 
been clearly resolved.
    Recently, apolipoprotein A1 (apoA1) polymorphism was identified as a factor affecting 
brain cholesterol metabolism and angiogenesis, leading to an increased risk for AD   [13]  . Up 
to now, several SNPs have been identified in the apoA1 gene located on the long arm of chro-
mosome 11. Among these, a common G/A substitution located at –75 bp upstream from the 
apoA1 transcription start site (rs670) and a C/T and G/A base substitution at position +83 bp 
(rs5069) or +84 bp (rs1799837) were reported to differentially affect apoA1 expression   [14, 
15]  . In view of this, Vollbach et al.   [16]   reported an increase in the risk of early-onset AD for 
rs670 A allele bearers, but did not find any impact of rs5069 and rs1799837 polymorphisms 
on risk of AD. In addition, in vitro, studies linked the amyloid-     (A   ) aggregation to the re-
duction of apoA1 levels in the brain, hence promoting neurodegeneration  [17] . Furthermore, 
apoA1 is associated with an earlier onset of neurofibrillary tangle formation and an in-
creased neurofibrillary tangle load.
    In this case-control study, we investigated whether the –75 G/A polymorphism of the 
apoA1 gene may be responsible for susceptibility to AD in a sample of patients that was al-
ready genotyped for apoE, bleomycin hydrolase, and vascular endothelial growth factor 
(VEGF)   [18, 19]  , and to assess its relationship with the severity of the disease as estimated by 
the Mini-Mental State Examination (MMSE) score.
  Subjects  and  Methods 
  The patients, Tunisian Arab descendants who live in the center of Tunisia, were con-
secutively evaluated at the Department of Neurology of Sahloul University Hospital 
  between January 2005 and August 2008. All participants underwent a complete clinical 
investigation, including medical history, neurological and neuropsychological examina-
tion, MMSE, laboratory tests and neuroimaging which consisted of magnetic resonance 
imaging (MRI). Our patients were assigned either to the AD or the control group accord-
ing to clinical examination and brain imaging. MRI has shown a great reduction in 
medial temporal lobe and hippocampal volume of patients with AD as compared to con-
trols. The MMSE for grading the cognitive state   [20]   was used in a validated Arabic ver-
sion   [21] .
    After this assessment, 173 patients were classified as probable AD (99 females and 74 
males; mean age 75   8   1.87 years, n = 173) according to the criteria of the National Institute 
of Neurological and Communicative Disorders and Stroke – Alzheimer’s Disease and Re-
lated Disorders Association (NINCDS-ADRDA)   [22]  . These patients were further classified 251
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according to their MMSE scores as follows: mild AD (MMSE   6  24), moderate AD (MMSE 
11–23), and severe AD (MMSE   ^ 10).
    The second group included 150 elderly subjects (79 females and 71 males; mean age 71   8  
1.78 years) that were selected as controls (MMSE  1 26) by experienced neurologists. These sub-
jects were hospitalized for clinical suspicion of meningitis or polyneuropathy (acute or chron-
ic). In both cases, a lumbar puncture was clinically indicated. Inclusion criteria were a normal 
renal or liver function (creatinine   ! 120    mol/l,  ALT   !  45 IU/l, AST   !  40 IU/l). Exclusion crite-
ria were the presence of an active neurological or psychiatric disease, memory complaints or 
other cognitive symptoms. The control subjects had a preserved general cognitive function and 
no family history of dementia. None of them complained of memory impairment at the time 
of examination. The control subjects were matched by age with the patients with dementia.
    The Institution’s Ethics Committee for studies in human subjects gave its approval for 
the study. A written informed consent to participate in this clinical research study was ob-
tained from participants or from a relative (legal guardian).
    Demographic details for all subjects were recorded, including age, gender, age at onset, 
MSSE score, duration of dementia, and plasma lipid and lipoprotein levels (  table 1 ).
    Blood samples were obtained after an overnight fast. Plasma levels of total cholesterol, 
triglycerides, and high-density lipoprotein cholesterol (HDL-C) were measured by standard-
ized enzymatic procedures, and apoA1 was measured using a turbidimetric assay on a Hita-
chi 912 analyzer. Low-density lipoprotein cholesterol (LDL-C) was calculated according to 
Friedewald’s formula   [23]  .
    Cerebrospinal fluid (CSF) was obtained from 88 controls and 143 AD patients. The CSF 
was stored in polypropylene tubes at –80    °    C and analyzed after the clinical follow-up of the 
study had been completed. CSF t-tau and A    42 levels were determined using a commercial-
ly available sandwich enzyme-linked immunoabsorbant assay (Innotest hTAU-Ag, Innotest 
    -amyloid 42) from Innogenetics.
  Total genomic DNA was isolated from peripheral blood leukocytes using genomic DNA 
purification kit (Promega). apoA1 genotype analysis was performed by PCR restriction frag-
ment length polymorphism analysis using the primer 5   -AG GG AC AG AG CT GA TCC TT-
GAACTCTTAAG-3    , and 5   -TTAGGGGACACCTACCCGTCAGGAAGACGA-3   . The 180-
bp amplified fragment was restricted with the enzyme MspI, and the DNA fragments were 
Table 1. D  emographic and clinical data by diagnostic groups
Variable Controls (n = 150) AD (n = 173) p
Women/men 79/71 99/74 NS
Age, years 7181.78 7581.87 NS
Age at onset, years – 7180.93 –
Duration of AD, years – 3.180.53 –
Higher education, n (%) 51 (34) 37 (21) –
MMSE 2880.32 1581.8 <0.001
TC, mmol/l 4.8681.11 4.5881.21 NS
TG, mmol/l 1.5980.76 1.1980.7 <0.001
LDL-C, mmol/l 3.2480.91 3.4780.9 NS
HDL-C, mmol/l 1.2380.29 0.8280.22 <0.001
apoA1, g/l 1.4380.2 1.1880.43 <0.001
D  ata are expressed as means 8 SD unless otherwise indicated. TC = Total cholesterol; TG = triglyc-
erides.252
Dement Geriatr Cogn Disord Extra 2011;1:249–257
 DOI:  10.1159/000329910 
EXTRA
  Smach et al.: Polymorphism in apoA1 and HDL-C Levels 
www.karger.com/dee
    © 2012 S. Karger AG, Basel
  Published online: January 17, 2012 
separated using 20% polyacrylamide gel electrophoresis. apoA1 genotype was determined by 
comparison with the combination of fragment sizes described by Vollbach et al.  [16] . All sub-
jects were genotyped for apoE using the methods described previously   [24]  .
  S t a t i s t i c s  
  Statistical analyses were performed by SPSS software for Windows (release 10.1). Allele 
frequencies were calculated by the gene counting method. Genotype and allele frequencies 
of apoA1 were compared between patients and controls using    2  test. After adjusting for age, 
gender, and educational level, univariate logistic regression analysis was performed for apoA1 
with AD by the apoE genotype. We used the statistical software Epinfo for power analysis. 
Statistical significance was set at p   !   0.05.
  R e s u l t s  
  In total of 173 patients with AD and 150 healthy controls were included in this study. 
The characteristics of the AD patients and control subjects are shown in   table 1  . The two 
groups were matched for gender (    2   = 0.323; p = 0.11) and age (    2   = 2.15; p = 0.73), with AD 
patients having a lower MMSE score together with lower serum apoA1, lower HDL-C levels, 
and higher triglyceride levels. Differences remained significant even when we took into ac-
count other parameters, such as age and sex, as covariants. In the AD patients, no significant 
differences in apoA1 concentrations between patients with one or two     4 alleles and those 
without the allele were found (data not shown; p = 0.72).
    Our study demonstrated that apoA1 concentrations were highly correlated (p   !   0.001) 
with the severity of AD, as reflected by the patients’ MMSE (  fig. 1  ). This relationship was in-
dependent of all other parameters studied (age, gender, and apoE genotypes). Moreover, pa-
tients with fewer years of education appeared to have higher rates of AD (OR = 2.48, 95% CI 
1.75–4.79; p = 0.007; adjusted for age: OR = 1.89, 95% CI 1.15–3.1; p = 0.004).
   Table 2   depicts the genotype distribution of apoA1 in AD patients and in the control 
group. Using the     2   test, the distribution of the apoA1 –75 G/A genotypes in all patients with 
AD and healthy controls did not significantly deviate from that expected by Hardy-Weinberg 
equilibrium. The frequencies of the GG, GA, and AA genotypes in the control group and 
among AD patients were 67.4, 25.4, and 7.2% and 61.3, 32.3, and 6.4%, respectively, in the 
apoA1 –75 G/A SNP. As shown in   table 2  , there were no statistically significant differences in 
the AD group when compared to controls (Pearson’s     2   test, p   !   0.05). According to the uni-
variate logistic regression analysis, the –75 A/G allele of the apoA1 polymorphism was not as-
Table 2. Allele and genotype frequencies of the apoA1 rs670 polymorphism








G 268 (77.5%) 240 (80%)
A 78 (22.5%) 60 (20%) 1.16 (0.78–1.73) 0.43
Genotype distribution 
GG 106 (61.3%) 101 (67.4%) 1
GA 56 (32.4%) 38 (25.4%) 1.4 (0.84–2.37) 0.16
AA 11 (6.4%) 11 (7.2%) 0.69 (0.27–1.78) 0.4
AA+GA 67 49 1.3 (0.8–2.12) 0.25253
Dement Geriatr Cogn Disord Extra 2011;1:249–257 
 DOI:  10.1159/000329910 
EXTRA
  Smach et al.: Polymorphism in apoA1 and HDL-C Levels 
www.karger.com/dee
  © 2012 S. Karger AG, Basel 
  Published online: January 17, 2012 
sociated with the risk of AD after adjusting for age, sex, and educational level (–75 G/A, pres-
ence of A allele: OR = 1.16, 95% CI 0.78–1.73; p = 0.43). Despite the presence of the apoE    4, 
the –75 G/A allele was not associated with AD after adjusting for age, sex, and educational 
level. The lack of an association observed could be linked to the low prevalence of the A allele.
    Investigation of the effect of the apoA1 polymorphism on apoA1 concentrations and 
HDL-C levels revealed that HDL-C levels were lower in AD patients who were carriers of at 
least one A allele of the apoA1 –75 G/A polymorphism than in carriers of the GG genotype 
(F = 7.1, d.f. = 1; p   !   0.05). Similar differences across the apoA allele were seen with HDL-C 
within the control group. We did not find any effect of the apoA1 –75 G/A polymorphism on 
the apoA1 level within the AD group or the control group associated with the absence or 
presence of the allele (F = 0.341, d.f. = 1; p = 0.78).
    Within the AD group, the A allele of apoA1 was associated with the CSF A   42  reduc-
tion (F = 1.26, d.f. = 1; p = 0.028). There was a significant CSF A    42 reduction in the AD 
Table 3. C  SF A42, CSF t-tau, serum apoA1 and HDL-C levels arranged by diagnosis and polymorphisms status (absent or 
present)
AD group C  ontrol group
n total  A (+) A (–) n total A (+) A (–)
A42, pg/ml 143 410 (330–690)a 315 (270–410)b 419 (330–475) 88 978 (790–1,055) 890 (810–1,020)c 960 (890–1,040)
t-tau, pg/ml 143 445 (370–680)a 460 (240–910) 458 (315–880) 88 280 (250–310) 280 (175–410) 265 (190–445)
HDL-C, mmol/l 173 0.8280.22a 0.7080.16b 0.8480.24 150 1.2380.29 0.180.22c 1.2780.19
apoA1, g/l 173 1.1880.43a 1.280.39 1.2380.19 150 1.4380.2 1.480.17 1.3980.19
Va  lues are medians and 25th to 75th percentiles in parentheses or means 8 SD. Bonferroni-corrected p values: a Highly significant differ-
ences (p < 0.001): AD vs. control group. b Significant differences (p < 0.05): AD A (+) vs. AD A (–). c Significant differences (p < 0.05): control
A (+) vs. control A (–).
  Fig. 1.   Relationship between se-
rum apoA1 concentrations and 
MMSE score. The correlation co-
efficient and the significance lev-
el are shown. 254
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patients with at least one copy of the A allele for apoA1 –75 G/A when compared with those 
AD patients without the allele [315 (270–410) vs. 419 (330–480); p = 0.033]. Contrarily, there 
were no significant differences in CSF t-tau protein levels within the AD group associated 
with the absence or presence of the allele (  table 3 ).
  Discussion 
  apoA1, a major apolipoprotein constituent of HDLs, is secreted into the bloodstream by 
the liver and intestine as a protein that is rapidly converted to mature apoA1. Different poly-
morphisms in apoA1 have been described, and influences on HDL and apoA1 plasma levels 
and on the risk of disorders such as coronary artery disease   [25]   or AD   [16]   have been de-
tected. However, only few of these findings have been replicated, and it is unclear which 
polymorphism might act as the relevant functional one. According to a study by Juo et al. 
 [26] ,   the A allele of the –75 G/A gene may affect expression of apoA1, although it was not clear 
whether the observed effect was directly associated with the mutation or due to another mu-
tant allele in linkage disequilibrium with the –75 G/A polymorphism. In this regard, while 
additional studies on a larger number of cases will be required to confirm and extend our 
findings, the present data suggest for the first time that this polymorphism has no influence 
on the expression of apoA1. Furthermore, this polymorphism was reported to be associated 
with changes in plasma HDL levels in particular in AD patients. HDL is the prominent lipo-
protein in the human brain   [27]   and is involved in the regulation of A     protein metabolism 
and deposition in the brain   [28]  . Deficit in HDL-C could also affect memory through its in-
fluence on atherosclerotic disease and stroke  [29]  or subclinical vascular injury not reflected 
in the covariates examined. Other possible mechanisms linking low levels of HDL-C to neu-
rodegenerative processes might involve its anti-inflammatory   [30]   or antioxidant   [31]   prop-
erties. In our current study, AD patients showed a significant decrease in HDL levels com-
pared with controls. The subjects included in our study had a diet which was characterized 
by a low intake of meat, a high intake of vegetables and legumes, and no alcohol intake. None 
of the subjects were malnourished and the dietary habits of control subjects and patients were 
similar. Interestingly, our results showed also that the apoA1 –75 G/A polymorphism has a 
reducing effect on HDL-C levels in AD patients (–0.14 mmol/l). These findings prompted us, 
therefore, to evaluate with a case-control study whether this polymorphic variation may have 
an impact on the susceptibility to AD in a Tunisian population.
    Reviewing previous reports, it seems evident that the apoA1 (–75 G/A) A allele frequen-
cy demonstrates heterogeneity around the word  [16, 32, 33] . In the present study, the –75 G/A 
variant was present at a frequency of 0.225 and 0.2 among AD and control subjects, respec-
tively. This was comparable also to frequencies established for a French  [32]  and Italian pop-
ulation   [33]  , but higher than the rates of 0.17–0.19 reported for a German population   [16]  . 
Although a previous study involving 500 healthy controls and 427 AD patients of Caucasian 
origin (UK and Germany) suggested an association between the rs670 A polymorphism and 
AD (age at onset   !  65 years; OR = 2.99, 95% CI 1.82–4.93; p   !   0.001)   [16]  , we were unable to 
reproduce these results in our population sample. Similar negative findings with respect to 
a direct association between potential genetic risk factor and disease have been reported pre-
viously   [32]  . The failure to replicate association in our population does not necessarily in-
validate the previous results. It might be attributed to several factors, such as differences in 
the ethnic background and geographic characteristics of the studied populations. Also, dif-
ferences in the inclusion and exclusion criteria may influence the study results, especially if 
subjects affected by some chronic diseases are not excluded from studies investigating genes 
involved in cholesterol metabolism. In addition, the absence of a statistically significant ef-255
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fect of the apoA1 polymorphism on the risk of AD in our sample can be attributed to low 
power because our sample had   !  80% power to detect an association with AD. Finally, it is 
not possible to exclude the role played by genes that are in relation with the apoA1 gene. In 
this condition, it is possible that one or more of these genes are in linkage disequilibrium 
with the apoA1 gene in some populations but not in others, thus influencing the results of 
these association studies.
    The second point of our study was to assess the relationships between the presence of 
this polymorphism, the genotype found in both groups of patients, and the pathological CSF 
markers of the disease. To our knowledge, the contribution of apoA1 in neurological disor-
ders and in AD patients has been evaluated in only a few of the autopsied brains, and most 
in vivo studies have been performed on plasma total. In the present study, one very impor-
tant association was observed between CSF A    42 levels and the –75 G/A polymorphism of 
apoA1. A significant decrease was observed in the CSF A    42 levels among the AD patients 
with the –75 A allele of apoA1. The –75 A allele of apoA1 effect sizes were similar when com-
paring CSF A    42 levels of AD patients and control subjects. On the other hand, there were 
no significant differences in CSF t-tau levels between the AD subjects and the control group 
associated with the presence or absence of the –75 A allele of apoA1. We propose that the 
increase in apoA1 transcription for the A allele may affect the solubility of A    42 and/or its 
transport across the blood-brain barrier in AD. apoA1 could be involved in the pathology of 
AD in at least three ways. A first mechanism would entail the formation of amyloid-like fi-
brils. apoA1 has been shown to participate in the amylogenesis process by binding to A    [3 4]   
and to form amyloid-like fibrils in APP transgenic mice   [8]  . A second role of apoA1 with 
implications in the genesis of AD relates to neuron maintenance. apoA1 is one of the ex-
changeable apolipoproteins that are actively involved in the regeneration process of neuron 
cells occurring after injury   [35]  . Finally, the association between apoA1 and other proteins 
such as apoJ and apoE   [36]   could contribute to the pathogenesis of AD. Other pathological 
mechanisms are possible and would need to be further evaluated in future AD studies.
  Regarding prognostic parameters, we have analyzed the correlations between the apoA1 
levels and clinical characteristics of dementia including MMSE score in AD patients. Studies 
in the elderly have shown that high levels of serum apoA1 and HDL-C are associated with 
low total mortality and enhanced longevity   [37, 38]  . Our results suggest that the AD patients 
with higher serum apoA1 concentrations have less cognitive impairment. This supports ear-
lier findings by Merched et al.   [15]   showing that higher serum apoA1 concentrations are as-
sociated with a significant improvement in cognitive performance. Moreover, when patients 
were stratified according to their MMSE score, AD patients with a lower score had signifi-
cantly decreased apoA1 levels. This finding may highlight the occurrence of some factors 
that may decrease the level or affinity of unknown molecular factors that affect synthesis and 
secretion of apoA1 in an allele-specific manner.
    In summary, the present study does not support any impact of the apoA1 genetic poly-
morphism on AD in the Tunisian population and confirmed the relationship between apoA1 
levels and MMSE score in AD patients. Further studies that identify the relevant functional 
apoA1 polymorphism are needed. These results will help to clarify the role of apoA1 poly-
morphisms in the regulation of cholesterol metabolism.
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